LDN-214117

ArtNr	HY-16712-100mg
Hersteller	MedChem Express
CAS-Nr.	1627503-67-6
Menge	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Kategorie	Neuroscience Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	99.92
Formula	C25H29N3O3
Citations	[1]Agustin H Mohedas, et al. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. <br/>[2]Jelena Mihajlović, et al. Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. J Cancer Res Clin Oncol. 2019 Nov;145(11):2675-2687.<br/>[3]Diana Carvalho, et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun Biol. 2019 May 9;2:156.
Smiles	CC(C(C1=CC(OC)=C(OC)C(OC)=C1)=C2)=NC=C2C3=CC=C(N4CCNCC4)C=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1627503-67-6
Lieferbar
Product Description	LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC50 value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC50 value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) [1][2]
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	419.52
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Target	TGF-β Receptor
Manufacturers Target	TGF-β Receptor
Isoform	ALK1; ALK2; ALK3; ALK5
Manufacturers Pathway	TGF-beta/Smad
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-16712-100mg-safety-datasheet.pdf